Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen

@inproceedings{Boyd2001SomePC,
  title={Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen},
  author={Michael R. Boyd and Kenneth D. Paull},
  year={2001}
}
During 1985-1990 the U.S. National Cancer Institute (NCI) phased out its murine leukemia P388 anticancer drug screening program and developed as the replacement a new in vitro primary screen based upon a diverse panel of human tumor cell lines. For each substance tested, the screen generates a remarkably reproducible and characteristic profile of differential in vitro cellular sensitivity, or lack thereof, across the 60 different cell lines comprising the panel. Several investigational… CONTINUE READING
Highly Influential
This paper has highly influenced 23 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 268 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Data display and analysis strategies for the NCI disease-oriented in vitro antitumor drug screen

  • MR Boyd, KD Paull, LR Rubinstein
  • 1992
Highly Influential
4 Excerpts

Feasibility of a high-flux anticancer drug screen utilizing a diverse panel of human tumor cell lines in culture

  • A Monks, D Scudiero, +10 authors MR Boyd
  • J Natl
  • 1991
Highly Influential
5 Excerpts

Status of the NCI preclinical antitumor drug discovery screen

  • MR Boyd
  • Cancer: Principles and Practice of Oncology…
  • 1989
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…